WallStSmart

Alcon AG (ALC)vsLeMaitre Vascular Inc (LMAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 4067% more annual revenue ($10.40B vs $249.60M). LMAT leads profitability with a 23.1% profit margin vs 9.4%. ALC appears more attractively valued with a PEG of 1.70. LMAT earns a higher WallStSmart Score of 61/100 (C+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

LMAT

Buy

61

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
LMATUndervalued (+25.6%)

Margin of Safety

+25.6%

Fair Value

$117.94

Current Price

$111.08

$6.86 discount

UndervaluedFair: $117.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

LMAT4 strengths · Avg: 8.3/10
Profit MarginProfitability
23.1%9/10

Keeps 23 of every $100 in revenue as profit

Operating MarginProfitability
21.8%8/10

Strong operational efficiency at 21.8%

Revenue GrowthGrowth
15.7%8/10

15.7% revenue growth

EPS GrowthGrowth
41.4%8/10

Earnings expanding 41.4% YoY

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

LMAT2 concerns · Avg: 2.0/10
PEG RatioValuation
3.072/10

Expensive relative to growth rate

P/E RatioValuation
42.2x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : LMAT

The strongest argument for LMAT centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 21.8%. Revenue growth of 15.7% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : LMAT

The primary concerns for LMAT are PEG Ratio, P/E Ratio. A P/E of 42.2x leaves little room for execution misses.

Key Dynamics to Monitor

ALC profiles as a value stock while LMAT is a growth play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

LMAT is growing revenue faster at 15.7% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

LMAT scores higher overall (61/100 vs 49/100), backed by strong 23.1% margins and 15.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

LeMaitre Vascular Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

Want to dig deeper into these stocks?